Clinical value of CD133 and nestin in patients with glioma: A population-based study

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 7, 2014, Pages 3739-3751

  Dahlrot, Rikke H ^a,b   Hansen, Steinbjørn ^a,b   Jensen, Stine S ^a,b   Schrøder, Henrik D ^a,b   Hjelmborg, Jacob ^b   Kristensen, Bjarne W ^a,b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Cancer stem cell; CD133; Glioblastoma; Glioma; Nestin; Population based

Indexed keywords

CD133 ANTIGEN; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; NES PROTEIN, HUMAN; NESTIN; PEPTIDE; TUMOR MARKER;

AGED; BIOSYNTHESIS; BRAIN TUMOR; CANCER STEM CELL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GLIOMA; HUMAN; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS;

AGED; ANTIGENS, CD; BRAIN NEOPLASMS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GLIOMA; GLYCOPROTEINS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASTIC STEM CELLS; NESTIN; PEPTIDES; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84906255620     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Bao S, Wu Q, Li Z, Sathornsumetee S, Wang H, McLendon RE, Hjelmeland AB and Rich JN. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res 2008; 68: 6043-6048.
2. Dean M, Fojo T and Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5: 275-284.
3. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988.
4. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA and Dick JE. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-648.
5. Christensen K, Schroeder HD and Kristensen BW. CD133 identifies perivascular niches in grade II-IV astrocytomas. J Neurooncol 2008; 90: 157-170.
6. Kim KJ, Lee KH, Kim HS, Moon KS, Jung TY, Jung S and Lee MC. The presence of stem cell marker-expressing cells is not prognostically significant in glioblastomas. Neuropathology 2011; 31: 494-502.
7. Ma YH, Mentlein R, Knerlich F, Kruse ML, Mehdorn HM and Held-Feindt J. Expression of stem cell markers in human astrocytomas of different WHO grades. J Neurooncol 2008; 86: 31-45.
8. Pallini R, Ricci-Vitiani L, Banna GL, Signore M, Lombardi D, Todaro M, Stassi G, Martini M, Maira G, Larocca LM and De MR. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res 2008; 14: 8205-8212.
9. Thon N, Damianoff K, Hegermann J, Grau S, Krebs B, Schnell O, Tonn JC and Goldbrunner R. Presence of pluripotent CD133+ cells correlates with malignancy of gliomas. Mol Cell Neurosci 2010; 43: 51-59.
10. Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N, Lichter P, Unterberg A, Radlwimmer B and Herold-Mende CC. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 2008; 14: 123-129.
11. Almqvist PM, Mah R, Lendahl U, Jacobsson B and Hendson G. Immunohistochemical detection of nestin in pediatric brain tumors. J Histochem Cytochem 2002; 50: 147-158.
12. Chinnaiyan P, Wang M, Rojiani AM, Tofilon PJ, Chakravarti A, Ang KK, Zhang HZ, Hammond E, Curran W Jr and Mehta MP. The prognostic value of nestin expression in newly diagnosed glioblastoma: report from the Radiation Therapy Oncology Group. Radiat Oncol 2008; 3: 32.
13. Ehrmann J, Kolar Z and Mokry J. Nestin as a diagnostic and prognostic marker: immunohistochemical analysis of its expression in different tumours. J Clin Pathol 2005; 58: 222-223.
14. Maderna E, Salmaggi A, Calatozzolo C, Limido L and Pollo B. Nestin, PDGFRbeta, CXCL12 and VEGF in glioma patients: different profiles of (pro-angiogenic) molecule expression are related with tumor grade and may provide prognostic information. Cancer Biol Ther 2007; 6: 1018-1024.
15. Mangiola A, Lama G, Giannitelli C, De BP, Anile C, Lauriola L, La TG, Sabatino G, Maira G, Jhanwar-Uniyal M and Sica G. Stem cell marker nestin and c-Jun NH2-terminal kinases in tumor and peritumor areas of glioblastoma multiforme: possible prognostic implications. Clin Cancer Res 2007; 13: 6970-6977.
16. Wei LC, Shi M, Cao R, Chen LW and Chan YS. Nestin small interfering RNA (siRNA) reduces cell growth in cultured astrocytoma cells. Brain Res 2008; 1196: 103-112.
17. Yang XH, Wu QL, Yu XB, Xu CX, Ma BF, Zhang XM, Li SN, Lahn BT and Xiang AP. Nestin expression in different tumours and its relevance to malignant grade. J Clin Pathol 2008; 61: 467-473.
18. Dahlstrand J, Collins VP and Lendahl U. Expression of the class VI intermediate filament nestin in human central nervous system tumors. Cancer Res 1992; 52: 5334-5341.
19. Strojnik T, Rosland GV, Sakariassen PO, Kavalar R and Lah T. Neural stem cell markers, nestin and musashi proteins, in the progression of human glioma: correlation of nestin with prognosis of patient survival. Surg Neurol 2007; 68: 133-143.
20. Wan F, Herold-Mende C, Campos B, Centner FS, Dictus C, Becker N, Devens F, Mogler C, Felsberg J, Grabe N, Reifenberger G, Lichter P, Unterberg A, Bermejo JL and Ahmadi R. Association of stem cell-related markers and survival in astrocytic gliomas. Biomarkers 2011; 16: 136-143.
21. Arai H, Ikota H, Sugawara K, Nobusawa S, Hirato J and Nakazato Y. Nestin expression in brain tumors: its utility for pathological diagnosis and correlation with the prognosis of high-grade gliomas. Brain Tumor Pathol 2012; 29: 160-167.
22. Kanamori M, Kumabe T, Sonoda Y, Nishino Y, Watanabe M and Tominaga T. Predictive factors for overall and progression-free survival, and dissemination in oligodendroglial tumors. J Neurooncol 2009; 93: 219-228.
23. Dahlrot RH, Kristensen BW, Hjelmborg J, Herrstedt J and Hansen S. A population-based study of high-grade gliomas and mutated isocitrate dehydrogenase 1. Int J Clin Exp Pathol 2013; 6: 31-40.
24. Dahlrot RH, Kristensen BW, Hjelmborg J, Herrstedt J and Hansen S. A population-based study of low-grade gliomas and mutated isocitrate dehydrogenase 1 (IDH1). J Neurooncol 2013; 114: 309-317.
25. Dahlrot RH, Hansen S, Herrstedt J, Schroder HD, Hjelmborg J and Kristensen BW. Prognostic value of Musashi-1 in gliomas. J Neurooncol 2013; 115: 453-461.
26. He J, Liu Y, Zhu T, Zhu J, Dimeco F, Vescovi AL, Heth JA, Muraszko KM, Fan X and Lubman DM. CD90 is identified as a candidate marker for cancer stem cells in primary high-grade gliomas using tissue microarrays. Mol Cell Proteomics 2012; 11: M111.010744.
27. Nakata S, Campos B, Bageritz J, Bermejo JL, Becker N, Engel F, Acker T, Momma S, Herold-Mende C, Lichter P, Radlwimmer B and Goidts V. LGR5 is a marker of poor prognosis in glioblastoma and is required for survival of brain cancer stem-like cells. Brain Pathol 2013; 23: 60-72.
28. Zhang B, Sun J, Yu SP, Chen C, Liu B, Liu ZF, Ren BC, Ming HL and Yang XJ. Rac1+ cells distributed in accordance with CD 133+ cells in glioblastomas and the elevated invasiveness of CD 133+ glioma cells with higher Rac1 activity. Chin Med J (Engl) 2012; 125: 4344-4348.
29. Christensen K, Schroder HD and Kristensen BW. CD133+ niches and single cells in glioblastoma have different phenotypes. J Neurooncol 2011; 104: 129-143.
30. Griguer CE, Oliva CR, Gobin E, Marcorelles P, Benos DJ, Lancaster JR Jr and Gillespie GY. CD133 is a marker of bioenergetic stress in human glioma. PLoS One 2008; 3: e3655.
31. Mao XG, Zhang X, Xue XY, Guo G, Wang P, Zhang W, Fei Z, Zhen HN, You SW and Yang H. Brain tumor stem-like cells identified by neural stem cell marker CD15. Transl Oncol 2009; 2: 247-257.
32. Beier D, Wischhusen J, Dietmaier W, Hau P, Proescholdt M, Brawanski A, Bogdahn U and Beier CP. CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors. Brain Pathol 2008; 18: 370-377.
33. WHO Classification of Tumours of the Central Nervous System. Edited by Louis DN, Ohgaki H, Wiestler OD and Cavenee WK. International Agency for Research on cancer (IARC) 2007.
34. Camp RL, Neumeister V and Rimm DL. A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol 2008; 26: 5630-5637.
35. Sauter G. Representativity of TMA studies. Methods Mol Biol 2010; 664: 27-35.
36. Camp RL, Chung GG and Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002; 8: 1323-1327.
37. Hayry V, Tynninen O, Haapasalo HK, Wolfer J, Paulus W, Hasselblatt M, Sariola H, Paetau A, Sarna S, Niemela M, Wartiovaara K and Nupponen NN. Stem cell protein BMI-1 is an independent marker for poor prognosis in oligodendroglial tumours. Neuropathol Appl Neurobiol 2008; 34: 555-563.
38. Chiesa-Vottero AG, Rybicki LA and Prayson RA. Comparison of proliferation indices in glioblastoma multiforme by whole tissue section vs tissue microarray. Am J Clin Pathol 2003; 120: 902-908.
39. Christensen K, Aaberg-Jessen C, Andersen C, Goplen D, Bjerkvig R and Kristensen BW. Immunohistochemical expression of stem cell, endothelial cell, and chemosensitivity markers in primary glioma spheroids cultured in serum-containing and serum-free medium. Neurosurgery 2010; 66: 933-947.
40. Hermansen SK, Christensen KG, Jensen SS and Kristensen BW. Inconsistent immunohistochemical expression patterns of four different CD133 antibody clones in glioblastoma. J Histochem Cytochem 2011; 59: 391-407.
41. Kolenda J, Jensen SS, Aaberg-Jessen C, Christensen K, Andersen C, Brunner N and Kristensen BW. Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids. J Neurooncol 2011; 103: 43-58.
42. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, Park JK and Fine HA. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006; 9: 391-403.
43. Bidlingmaier S, Zhu X and Liu B. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J Mol Med 2008; 86: 1025-1032.
44. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U and Beier CP. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007; 67: 4010-4015.
45. Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, Kasman IM, Greve JM, Soriano RH, Gilmour LL, Rivers CS, Modrusan Z, Nacu S, Guerrero S, Edgar KA, Wallin JJ, Lamszus K, Westphal M, Heim S, James CD, Van den Berg SR, Costello JF, Moorefield S, Cowdrey CJ, Prados M and Phillips HS. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 2010; 17: 362-375.
46. Joo KM, Kim SY, Jin X, Song SY, Kong DS, Lee JI, Jeon JW, Kim MH, Kang BG, Jung Y, Jin J, Hong SC, Park WY, Lee DS, Kim H and Nam DH. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Invest 2008; 88: 808-815.
47. Wang J, Sakariassen PO, Tsinkalovsky O, Immervoll H, Boe SO, Svendsen A, Prestegarden L, Rosland G, Thorsen F, Stuhr L, Molven A, Bjerkvig R and Enger PO. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 2008; 122: 761-768.
48. Ohgaki H and Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005; 64: 479-489.
49. Sugawara K, Kurihara H, Negishi M, Saito N, Nakazato Y, Sasaki T and Takeuchi T. Nestin as a marker for proliferative endothelium in gliomas. Lab Invest 2002; 82: 345-351.
50. Zhang M, Song T, Yang L, Chen R, Wu L, Yang Z and Fang J. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients. J Exp Clin Cancer Res 2008; 27: 85.
51. Milde T, Hielscher T, Witt H, Kool M, Mack SC, Deubzer HE, Oehme I, Lodrini M, Benner A, Taylor MD, von Deimling A, Kulozik AE, Pfister SM, Witt O and Korshunov A. Nestin expression identifies ependymoma patients with poor outcome. Brain Pathol 2012; 22: 848-860.
52. Rao J, Seligson D and Hemstreet GP. Protein expression analysis using quantitative fluorescence image analysis on tissue microarray slides. Biotechniques 2002; 32: 924-926, 928-930, 932.